Dumont & Blake Investment Advisors’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $652K | Buy |
4,300
+20
| +0.5% | +$3.04K | 0.17% | 127 |
|
|
2025
Q1 | $644K | Buy |
4,280
+5
| +0.1% | +$753 | 0.18% | 121 |
|
|
2024
Q4 | $789K | Sell |
4,275
-85
| -2% | -$15.7K | 0.21% | 107 |
|
|
2024
Q3 | $859K | Sell |
4,360
-4,360
| -50% | -$859K | 0.23% | 107 |
|
|
2024
Q2 | $1.8M | Buy |
8,720
+4,305
| +98% | +$889K | 0.26% | 96 |
|
|
2024
Q1 | $1.2M | Buy |
4,415
+62
| +1% | +$16.8K | 0.34% | 81 |
|
|
2023
Q4 | $1.03M | Sell |
4,353
-135
| -3% | -$31.9K | 0.32% | 87 |
|
|
2023
Q3 | $880K | Buy |
4,488
+25
| +0.6% | +$4.9K | 0.3% | 86 |
|
|
2023
Q2 | $938K | Buy |
4,463
+15
| +0.3% | +$3.15K | 0.3% | 85 |
|
|
2023
Q1 | $898K | Buy |
4,448
+2,085
| +88% | +$421K | 0.3% | 88 |
|
|
2022
Q4 | $515K | Sell |
2,363
-5
| -0.2% | -$1.09K | 0.18% | 123 |
|
|
2022
Q3 | $466K | Buy |
+2,368
| New | +$466K | 0.17% | 130 |
|